COMP <GO>
CNMD vs TMDX // NET PROFIT MARGIN
CONMED Corporation (NYSE) VS. TransMedics Group Inc. (NASDAQ) • 15-METRIC TALLY: CNMD 4
— TMDX 9
▲ NET PROFIT MARGIN LEADER: TMDX
LAST: $45.72 (-0.09%) • MKT CAP: $1.36B
net-margins
3.40%
LAST: $67.12 (+0.33%) • MKT CAP: $2.33B
net-margins
31.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CNMD VS. TMDX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CNMD | TMDX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.60% | 59.90% | -5.30 | TMDX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.80% | 18.10% | -10.30 | TMDX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 11.4x | 14.6x | -3.20 | CNMD | /valuation <GO> |
| Free Cash Flow Yield | 11.07% | 5.74% | +5.33 | CNMD | /fcf-yield <GO> |
| Operating Margin | 7.50% | 17.90% | -10.40 | TMDX | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 3.40% | 31.40% | -28.00 | TMDX | /net-margins <GO> |
| Revenue Growth (YoY) | 5.20% | 37.10% | -31.90 | TMDX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.82% | 0.00% | +1.82 | CNMD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.91 | 3.50 | -1.59 | TMDX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | TMDX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.6 | 28.9 | +11.67 | CNMD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.9x | 10.2x | +16.70 | TMDX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.36B | $2.33B | -$964.8M | TMDX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CNMD REV | TMDX REV | CNMD GROSS % | TMDX GROSS % | CNMD FCF | TMDX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.37B | $605.5M | 54.6% | 59.9% | $150.9M | $133.6M |
| FY 2024 | $1.31B | $441.5M | 56.1% | 59.4% | $153.9M | -$80.9M |
| FY 2023 | $1.24B | $241.6M | — | — | $125.3M | -$13.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CNMD // BETA —
TMDX // BETA —